Abstract
Introduction: Clinical trials for glabellar lines (GL) have classically recruited subjects who are naïve to treatment to maintain population homogeneity. The DaxibotulinumtoxinA for Injection (DAXI) phase 3 GL program did not restrict enrollment in this way and included subjects with previous botulinum neurotoxin (BoNT) treatment experience as well as those naïve to treatment. Comparing these two subgroups will help determine if prior experience is an influential baseline characteristic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
